The model's bets, stated in advance.

Sovereign and critical-infrastructure connectivity is re-rating as utilities, governments, and defense buyers harden and modernize their networks: satellite communications (IRDM), private-wireless spectrum (ATEX), and secure defense electronics (MRCY) are bid together on rising grid-security and defense capex. Broad participation across the group plus heavy volume confirm a genuine theme rather than a single-name squeeze.

How it resolves No bet-specific kill line: no price level is set for any name in this bet. Every theme bet runs on the same pre-registered mechanical exits — the basket down 50% against its entry cost, a single name down 70% against its entry price, the theme sleeve down 55% from its high-water mark, or a name breaking structurally (10 consecutive sessions under its 100-day average), the last of which becomes reachable only once the bet has been held its pre-registered minimum of 60 trading sessions. That minimum is a hold requirement, not a resolution date: nothing closes a bet because 60 sessions have elapsed. Fixed in advance: the date, the names, and the stated probability.

The AI data-center buildout is driving a genuine memory and storage supercycle: DRAM/HBM and NAND pricing are recovering while nearline HDD demand from hyperscalers stays tight. Micron and Seagate are the highest-quality, cash-generative center of this theme, with SIMO's NAND controllers and WDC riding the same storage upcycle and UMC providing broader foundry participation.

How it resolves No bet-specific kill line: no price level is set for any name in this bet. Every theme bet runs on the same pre-registered mechanical exits — the basket down 50% against its entry cost, a single name down 70% against its entry price, the theme sleeve down 55% from its high-water mark, or a name breaking structurally (10 consecutive sessions under its 100-day average), the last of which becomes reachable only once the bet has been held its pre-registered minimum of 60 trading sessions. That minimum is a hold requirement, not a resolution date: nothing closes a bet because 60 sessions have elapsed. Fixed in advance: the date, the names, and the stated probability.

Enterprise AI-infrastructure buildout: hyperscaler and enterprise capex is pouring into AI-optimized servers, storage and IT distribution, and Dell is the volume leader turning that demand into record backlog. NetApp, HPE, the channel (SNX) and identity/security (OKTA) all ride the same datacenter refresh cycle — real earnings, real breadth (4 peers +30% in 3m, 1.82x volume), not a single squeeze.

How it resolves No bet-specific kill line: no price level is set for any name in this bet. Every theme bet runs on the same pre-registered mechanical exits — the basket down 50% against its entry cost, a single name down 70% against its entry price, the theme sleeve down 55% from its high-water mark, or a name breaking structurally (10 consecutive sessions under its 100-day average), the last of which becomes reachable only once the bet has been held its pre-registered minimum of 60 trading sessions. That minimum is a hold requirement, not a resolution date: nothing closes a bet because 60 sessions have elapsed. Fixed in advance: the date, the names, and the stated probability.

Broad breadth (7 peers +30% in 3m) and 1.8x volume participation confirm real theme demand, not a single squeeze.

How it resolves No bet-specific kill line: no price level is set for any name in this bet. Every theme bet runs on the same pre-registered mechanical exits — the basket down 50% against its entry cost, a single name down 70% against its entry price, the theme sleeve down 55% from its high-water mark, or a name breaking structurally (10 consecutive sessions under its 100-day average), the last of which becomes reachable only once the bet has been held its pre-registered minimum of 60 trading sessions. That minimum is a hold requirement, not a resolution date: nothing closes a bet because 60 sessions have elapsed. Fixed in advance: the date, the names, and the stated probability.

Managed-care and ACA-marketplace insurers are re-rating together on a margin-recovery narrative, with sector-wide breadth and heavy volume rather than a single-name squeeze.

How it resolves No bet-specific kill line: no price level is set for any name in this bet. Every theme bet runs on the same pre-registered mechanical exits — the basket down 50% against its entry cost, a single name down 70% against its entry price, the theme sleeve down 55% from its high-water mark, or a name breaking structurally (10 consecutive sessions under its 100-day average), the last of which becomes reachable only once the bet has been held its pre-registered minimum of 60 trading sessions. That minimum is a hold requirement, not a resolution date: nothing closes a bet because 60 sessions have elapsed. Fixed in advance: the date, the names, and the stated probability.

A genuine freight-cycle upturn after a multi-year trucking recession: brokerage, LTL and truckload volumes and spot rates are re-accelerating, lifting asset-light and asset-based carriers together. RXO leads as the highest-beta brokerage play; XPO's LTL execution is the durable compounding anchor.

How it resolves No bet-specific kill line: no price level is set for any name in this bet. Every theme bet runs on the same pre-registered mechanical exits — the basket down 50% against its entry cost, a single name down 70% against its entry price, the theme sleeve down 55% from its high-water mark, or a name breaking structurally (10 consecutive sessions under its 100-day average), the last of which becomes reachable only once the bet has been held its pre-registered minimum of 60 trading sessions. That minimum is a hold requirement, not a resolution date: nothing closes a bet because 60 sessions have elapsed. Fixed in advance: the date, the names, and the stated probability.

Corporate-action artifact. The trigger and every corr-to-leader are synthetic. Remaining members are unrelated binary-readout biotechs (DFTX Ph3, ORKA, APGE) plus an insurance broker. No theme.

Index/ETF-flow (common-factor) artifact. Eight names, eight unrelated sectors: plasma-donation card processor, diapers, game engine, payroll SaaS, ad exchange, background screening, timeshare, oncology device. No shared narrative — leader correlations cap at 0.67 and cluster near 0.5, the signature of a high-beta small-cap rebound on risk-on flows. Any AI-software sub-story excludes the leader.

Uniform ~0.41 corr to leader = market/small-cap momentum beta, not a theme; breadth only 2/3 and MTRN already rolled (+11% 3m).

Binary-event biotech lottery + sector-bucket artifact. XNCR and DTIL are independent readout/royalty events, not co-movers. HAE (blood-management devices) and WEAV (practice SaaS) share only the GICS Health Care bucket; corr 0.41-0.55, breadth 2.

Sector-beta/fund-flow artifact plus binary biotech. HQL is a closed-end biotech FUND holding this sector — a mechanical index twin. MBX (+109% 3m) and DYN are clinical-stage readout lotteries. URGN/TVTX/TGTX share no driver beyond XBI beta (bladder cancer vs IgAN vs MS). BLMN (restaurants) and MTRN (materials) prove the link is a risk-on factor. Corrs 0.41-0.54.

Corporate-action artifact + binary biotech. The only truly correlated names (APGE 0.90, DFTX 0.81, ORKA) are clinical-stage I&I biotechs — readout lotteries — and BWIN (insurance broker) shares no narrative with an office REIT. Co-movement, not a theme.

Single low-float post-IPO squeeze masquerading as breadth. Peers share no narrative: XMTR (industrial marketplace), GDRX (Rx discounts), SOPH (genomics) each rallied on their own Q2 prints; corr just 0.42-0.44.

Factor/beta artifact, not a theme: managed care (HUM), IT distribution (NSIT), college retail (BNED), game engine (U), CPaaS (TWLO), social SaaS (SPT), job board (ZIP) share no demand driver. Tell: uniform ~0.40-0.46 correlations across unrelated sectors = one beaten-down/high-short-interest mean-reversion factor in a broad up-tape. An "AI software" story needs discarding 3 of 7 members.

Binary-event biotech basket with no narrative link. Four unrelated-indication biotechs (URGN bladder cancer, TGTX MS, ACRS derm, DYN muscle) plus a beryllium/specialty-materials name (MTRN) and a steakhouse chain (BLMN). Correlations 0.40-0.55 are drift, not theme; moves are idiosyncratic FDA/readout and single-name catalysts. No theme to compound.

Correlation artifact — no shared narrative. Members span four unrelated industries: transplant diagnostics (CDNA), temp staffing (MAN), clinical-stage psychedelics (ATAI), hospital products (BAX). Correlations to leader are only 0.40–0.53 — coincident beaten-down value/rebound factor beta, not a theme. ATAI is additionally a binary-readout biotech lottery.

Binary-event biotech. CMPS/ATAI/GHRS are clinical-stage psychedelics driven by Phase 2b/3 readouts and FDA-path news (COMP360, GH001); ERAS is another pre-revenue oncology binary. ATAI is equity/deal-entangled with CMPS, so not independent breadth, and BB (BlackBerry) is an unrelated software name at 0.40 corr padding the count. Readout lottery, not a compounding theme.

Factor/beta artifact, no shared narrative: staffing, oilfield chemicals, adtech, cybersecurity, beryllium, e-commerce, telehealth. All catalysts idiosyncratic — TBI is one +28.7% post-Q2 earnings gap, FTK a Puerto Rico power contract. Corr-to-leader caps at 0.50 (all 0.41-0.50 = market beta). Low-price microcap 3x off its low masquerading as breadth.

Factor-flow artifact, not a narrative: 8 unrelated industries (PAYS plasma/pharma payments, HNST diapers, VAC timeshare, MGNI adtech, FA screening, PAYC payroll, ASPN aerogels, U game engine). Corr 0.42-0.68 = high-beta/high-short-interest small-cap risk-on rotation, not a shared driver. Leader PAYS has zero business overlap with any member; standalone parabolic at its 252d high.

Index/ETF-flow artifact: a beaten-down small-cap value / high-short-interest factor rotation, not a theme. Members span gaming peripherals, adtech, lead-gen, luxury watches, healthcare staffing and diagnostics — no shared catalyst, customer or supply chain. Leader correlations of only 0.40-0.55 are generic small-cap beta, not one narrative.

Binary-event biotech basket. 7 of 8 members are clinical-stage readout lotteries (CLYM, DTIL, CLDX, AMLX, EWTX largely pre-revenue); the 8th, ATI, is aerospace/specialty metals with zero thematic link. Corr to leader is only 0.40-0.55 = XBI sector beta, not a shared narrative. Leader is pre-revenue, pinned at its 252d high after an ~8.7x, with a coin-flip trial readout as the next catalyst.

Share-class twin + no common narrative. BTSG/BTSGU are the same issuer (BrightSpring common vs units), padding breadth. The rest span Cushing's pharma (CORT), cinemas (MCS), utility hardware (PLPC), power EPC (AGX), bitcoin/AI datacenters (CORZ), sequencing (ILMN) — no shared driver. Corr 0.40-0.46 = market beta; CORT's move is a single-asset relacorilant catalyst.

Sector-incoherent SMID beta basket, no shared narrative. PRCH's +148% is idiosyncratic (reciprocal-exchange restructuring) and shares nothing with theatres/hotels (MCS), agency+ad-tech (STGW, DSP) or networking (EXTR, FFIV) — three unrelated sub-themes. Uniform 0.41-0.46 correlation is generic small-cap beta, not theme co-movement; only 2 of 5 peers participate over 3m, EXTR flat.

Binary-event biotech lottery plus unrelated sector strays. Five members are unconnected drug stories (URGN, TGTX, ACRS, DYN, IBRX) sharing no end market; SSRM (gold), MTRN (beryllium), BLMN (steakhouse) overlap with nothing. All peer correlations 0.42-0.54 = generic small-cap risk-on beta, not thematic co-movement. No narrative center to weight.

Binary-event biotech (readout/FDA lottery). GHRS, CMPS, ATAI are pre-revenue psychedelic-CNS names moving on Phase 2b/3 data and scheduling headlines, not a compounding theme; ATAI/CMPS are further linked by atai's equity stake, so breadth is one event book. NKTR (corr 0.43, 3m -8%) is unrelated immunology. All carry post-data ATM dilution risk.

Correlation artifact, not a theme: grab-bag of unrelated sectors — uniform services (VSTS/UNF/ARMK), edge semis (AMBQ), biotech (MGNX), medtech (PLSE), nursing (PACS), Vegas Sphere (SPHR) — sharing only risk-on beta (corr 0.41-0.57). Leader VSTS is M&A/event-driven, pinned near its 252d high (capped), MGNX is a binary biotech, breadth thin (2 peers).

Spurious-breadth / momentum-factor artifact, not a narrative theme. 8 members span ~6 unrelated industries (SEZL BNPL, DAVE neobank, TWST DNA synth, TXG genomics tools, LFST mental-health, SNEX commodity brokerage, XMTR mfg marketplace, OPRA browser), weak corr 0.42-0.60. Only SEZL/DAVE share a story (consumer fintech), too narrow to carry breadth; rest is unrelated small-cap momentum co-movement.

Spurious cross-sector momentum grab-bag — no shared theme. Members span dialysis (DVA), Spanish media (EVC), micro-cap truck parts (CVGI), EMS electronics (FLEX), MS biotech (TGTX), private prisons (GEO), gyms (LTH), pharma (JAZZ). The 0.43–0.73 corrs are bull-market beta, not a narrative; each name has its own catalyst. CVGI (+183%/6m, +7%/3m) is a spent squeeze; DVA is -1% off its 252d high.

Correlation artifact, no shared narrative. Leader LQDA is a binary FDA/litigation pharma (Yutrepia vs United Therapeutics); All peer corrs ~0.41-0.48; breadth is spurious.

no shared narrative driver, just bull-market beta. Also carries binary-biotech risk (TGTX/NBTX).

Binary-event biotech basket / FDA-readout lottery: DFTX, APGE, KYMR, CGEM, BCAX, BHVN are heterogeneous clinical-stage biotechs in different modalities with no shared commercial narrative — XBI sector beta, not a theme. OPI (+8900%, 0.81 corr) is a spurious squeeze artifact and LILAK an unrelated LatAm telecom padding fake breadth.

binary-event biotechs (FDA/readout lotteries): 8 unrelated clinical-stage, pre-revenue names — complement (DNTH), oncology antibodies (MGNX), ITK (CRVS), CML kinase (ELVN), radiation (DRTS), cough (TRVI), rare-derm (PVLA), gene therapy (MGTX). No shared narrative; low cross-corr (~0.45) = shared XBI sector beta, not a theme. Each is an idiosyncratic trial-readout lottery.

Correlation artifact — spurious co-momentum/beta cluster, no shared narrative. Members span unrelated sectors (FTNT cybersecurity, DDOG cloud-monitoring, CLDT hotel REIT, LFST mental-health, XMTR mfg marketplace, HNST baby products, CCRN healthcare staffing) and leader correlations are only 0.42-0.54, so the >100% breadth is a risk-on beta wave, not a theme.

Momentum-factor basket masquerading as breadth — no shared narrative. Members span 4 unrelated sectors: cybersecurity (CRWD/PANW/TENB), digital health (HNGE/OSCR/OMDA), remittances (RELY), staffing (TBI); only 0.40-0.56 corr to leader. Co-triggered by a common risk-on/momentum factor, not one story — no narrative makes a staffing agency, CrowdStrike and Hinge Health co-beneficiaries.

Correlation artifact — no shared narrative. Five unrelated sectors: PLSE bioelectric medical device, VSTS uniform rental, ARMK food/facilities, HLIO hydraulics, RAL test instruments. Peer corr only 0.41–0.44, breadth peers=2. VSTS is a standalone M&A/takeover story; PLSE a Duggan-controlled single-name device squeeze near its 252d high. Spurious co-movement, not a theme.

binary-event biotechs (FDA/readout lotteries): seven unrelated clinical-stage names (transplant, bladder-cancer IO, cough, oncolytic virus, DMD gene therapy, epilepsy, holdco), each driven by its own binary readout. Low cross-corr (0.40-0.52) = no shared driver; 6m move is small-cap biotech beta and 3m breadth is only 2 names. No narrative theme.

Single-name re-rating masquerading as breadth. Members span four unrelated sectors — 900MHz spectrum leasing (ATEX), LEO satellite (IRDM), application networking (ATEN), endocrine biotech (MBX) — with only weak pairwise corr (~0.43–0.49) and the leader (+364%) far outrunning peers. No shared narrative driver; MBX is a binary-event biotech. Correlation-artifact grab-bag.

binary-event biotech (FDA/readout lottery) basket — APGE/CGON/KYMR/BHVN are unrelated clinical-stage names (atopic derm, bladder cancer onco-virus, protein degradation, neuro) with no shared modality/indication; co-movement is XBI risk-on beta, not a narrative theme. Weak corr (0.48/0.48/0.44/0.41), only 3 peers >30% in 3m, and a lone +235% leader = single readout run masquerading as breadth.

Correlation artifact: healthcare grab-bag, no shared narrative. Leader CORT (cortisol pharma, idiosyncratic ROSELLA ovarian-cancer catalyst) carries it; peers are unrelated models — ACHC behavioral facilities, BTSG home-health services, DNLI binary neuro biotech, RPRX royalty aggregator. Uniform low corr ~0.40 = sector/factor beta, not a theme; breadth weak (2/4 >30%).

factor/beta momentum artifact, not a narrative theme. Members span 6 unrelated sectors (SEZL/DAVE fintech, SNEX brokerage, TWST synth-DNA biotech, DDOG SaaS, VAC timeshare, LFST mental-health, XMTR manufacturing) with only 0.40-0.58 corr to leader. Co-movement is risk-on high-beta ripping together, no shared story. Shaping would require dropping 5 of 8 names and manufacturing conviction.

Momentum-factor beta basket, no shared narrative. 8 unrelated sectors: dialysis (DVA), contract electronics (FLEX), private prisons (GEO), MS biotech (TGTX), gyms (LTH), healthcare REIT (DOC), pharma (JAZZ), food distro (PFGC). Moderate ~0.5 pairwise corr = common momentum/beta, not a driver; each top name has its own story. No theme center to curate.

binary-event biotechs (FDA/readout lotteries) — grab-bag of clinical-stage biotechs across unrelated indications (APGE immunology, CGON bladder-cancer, KYMR protein degradation, BHVN neuro), no shared compounding narrative. Co-movement is XBI sector-ETF flow beta plus idiosyncratic readout spikes; sub-0.5 corr on 3 of 4 peers = sector twins, not a theme.

binary-event biotech (FDA/readout lottery): leader SYRE and the two top-return narrative-center peers ORKA/APGE are pre-revenue clinical-stage I&I antibody names; remaining "breadth" (MKSI, CGNX, ARW, ESI) are unrelated profitable industrials sharing only risk-on beta (corr 0.41-0.54). Two incompatible sub-themes glued by beta, binary-biotech core.

index/ETF-flow twins — heterogeneous high-beta growth basket (DDOG observability, FTNT cybersecurity, LFST behavioral health, XMTR manufacturing marketplace, WRBY eyewear) sharing no end-market or narrative; weak ~0.41-0.47 leader correlations = co-movement is momentum/growth-ETF factor flow, not a real theme.

spurious cross-sector correlation / factor-beta grab-bag — no shared narrative theme. Members span 6+ unrelated industries: DVA dialysis, FLEX electronics EMS, TGTX MS biotech, GEO private prisons, VECO semi equipment, DOC healthcare REIT, LTH gyms, VCYT diagnostics. Moderate corr (0.40–0.66) reflects common market beta, not a compounding theme. No coherent bet to shape.